{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T19:24:00Z","timestamp":1770751440409,"version":"3.50.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"vor","delay-in-days":27,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Urol"],"DOI":"10.1186\/s12894-025-02040-x","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T13:08:27Z","timestamp":1768396107000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of intravesical Bacillus Calmette-Gu\u00e9rin and chemohyperthermia with mitomycin C in with high-risk non\u2013muscle-invasive bladder cancer: a critical assesment focusing on the quality of life and adverse events"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7067-3815","authenticated-orcid":false,"given":"Fahri Yavuz","family":"Ilki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2265-1264","authenticated-orcid":false,"given":"Emre","family":"B\u00fclb\u00fcl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3128-1661","authenticated-orcid":false,"given":"Yusuf Kadir","family":"Top\u00e7u","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2679-8388","authenticated-orcid":false,"given":"Ozgur","family":"Cinar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1449-2838","authenticated-orcid":false,"given":"Cetin","family":"Kocab\u0131y\u0131k","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4999-9217","authenticated-orcid":false,"given":"Selahattin","family":"Bedir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,14]]},"reference":[{"key":"2040_CR1","first-page":"2","volume-title":"EAU guidelines on Non\u2013muscle-invasive bladder cancer (TaT1 and CIS) \u2013 Limited update March 2025","author":"M Babjuk","year":"2025","unstructured":"Babjuk M, Burger M, Capoun O, Cohen D, Comp\u00e9rat EM, Dominguez-Escrig JL, et al. EAU guidelines on Non\u2013muscle-invasive bladder cancer (TaT1 and CIS) \u2013 Limited update March 2025. Arnhem (Netherlands): European Association of Urology Guidelines Office; 2025. pp. 2\u201376."},{"issue":"3","key":"2040_CR2","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","volume":"49","author":"RJ Sylvester","year":"2006","unstructured":"Sylvester RJ, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis. Eur Urol. 2006;49(3):466\u201375.","journal-title":"Eur Urol"},{"issue":"3","key":"2040_CR3","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/S0022-5347(17)37316-0","volume":"147","author":"DL Lamm","year":"1992","unstructured":"Lamm DL, et al. Complications of Bacillus Calmette\u2013Gu\u00e9rin immunotherapy in superficial bladder cancer. J Urol. 1992;147(3):596\u2013600.","journal-title":"J Urol"},{"issue":"3","key":"2040_CR4","first-page":"265","volume":"27","author":"R Colombo","year":"2009","unstructured":"Colombo R, et al. Thermochemotherapy in non\u2013muscle-invasive bladder cancer: update and perspectives. World J Urol. 2009;27(3):265\u201370.","journal-title":"World J Urol"},{"issue":"4","key":"2040_CR5","first-page":"964","volume":"205","author":"WS Tan","year":"2021","unstructured":"Tan WS, et al. Intravesical hyperthermia and chemotherapy vs. BCG for intermediate-risk bladder cancer: a network meta-analysis. J Urol. 2021;205(4):964\u201373.","journal-title":"J Urol"},{"key":"2040_CR6","doi-asserted-by":"publisher","first-page":"CD006885","DOI":"10.1002\/14651858.CD006885.pub2","volume":"5","author":"PF Shang","year":"2011","unstructured":"Shang PF, Kwong J, Wang ZP, Tian JH, Jiang L, Yang KH, et al. Intravesical Bacillus Calmette\u2013Gu\u00e9rin versus epirubicin for Ta and T1 bladder cancer. Cochrane Database Syst Rev. 2011;5:CD006885. https:\/\/doi.org\/10.1002\/14651858.CD006885.pub2.","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"2040_CR7","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1007\/s00345-022-03928-1","volume":"40","author":"F Guerrero-Ramos","year":"2022","unstructured":"Guerrero-Ramos F, Gonz\u00e1lez-Padilla DA, Gonz\u00e1lez-D\u00edaz A, de la Rosa-Kehrmann F, Rodr\u00edguez-Antol\u00edn A, Inman BA, Villacampa-Aub\u00e1 F. Recirculating hyperthermic intravesical chemotherapy with mitomycin C (HIVEC) versus BCG in high-risk non-muscle-invasive bladder cancer: results of the HIVEC-HR randomized clinical trial. World J Urol. 2022;40(4):999\u20131004.","journal-title":"World J Urol"},{"issue":"18","key":"2040_CR8","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1007\/BF03262330","volume":"21","author":"MF Botteman","year":"2003","unstructured":"Botteman MF, et al. The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics. 2003;21(18):1315\u201330.","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"2040_CR9","first-page":"2749","volume":"182","author":"EC Cauberg","year":"2009","unstructured":"Cauberg EC, et al. Adverse events associated with intravesical BCG treatment for bladder cancer: a systematic review. J Urol. 2009;182(6):2749\u201357.","journal-title":"J Urol"},{"issue":"3","key":"2040_CR10","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1097\/00005650-199603000-00003","volume":"34","author":"JE Ware","year":"1996","unstructured":"Ware JE, Kosinski M, Keller SD. A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996;34(3):220\u201333.","journal-title":"Med Care"},{"key":"2040_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2025.03.007","author":"M Longoni","year":"2025","unstructured":"Longoni M, Scilipoti P, Soria F, Pradere B, Krajewski W, D\u2019Andrea D, et al. Oncological outcomes in Bacillus Calmette-Gu\u00e9rin\u2013na\u00efve high-risk non\u2013muscle-invasive bladder cancer patients: a systematic review on current treatment strategies and future perspectives. Eur Urol Oncol. 2025. https:\/\/doi.org\/10.1016\/j.euo.2025.03.007.","journal-title":"Eur Urol Oncol"},{"issue":"9","key":"2040_CR12","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S1470-2045(11)70190-5","volume":"10","author":"SM Di Stasi","year":"2009","unstructured":"Di Stasi SM, et al. Intravesical thermochemotherapy vs. BCG for superficial bladder cancer: A phase III randomized controlled trial. Lancet Oncol. 2009;10(9):871\u20139.","journal-title":"Lancet Oncol"},{"issue":"3","key":"2040_CR13","first-page":"485","volume":"61","author":"M Brausi","year":"2011","unstructured":"Brausi M, et al. Side effects of Bacillus Calmette\u2013Gu\u00e9rin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder. Eur Urol. 2011;61(3):485\u201390.","journal-title":"Eur Urol"},{"issue":"15","key":"2040_CR14","first-page":"3849","volume":"19","author":"R Colombo","year":"2001","unstructured":"Colombo R, et al. Neoadjuvant electromotive mitomycin C vs. BCG before TUR in high-risk superficial bladder cancer: A randomized study. J Clin Oncol. 2001;19(15):3849\u201353.","journal-title":"J Clin Oncol"},{"issue":"2","key":"2040_CR15","doi-asserted-by":"publisher","first-page":"62.e13","DOI":"10.1016\/j.urolonc.2021.07.019","volume":"40","author":"OM Pijpers","year":"2022","unstructured":"Pijpers OM, Hendricksen K, Mostafid H, et al. Long-term efficacy of hyperthermic intravesical chemotherapy for BCG-unresponsive non-muscle invasive bladder cancer. Urol Oncol. 2022;40(2):62.e13\u2013e20. https:\/\/doi.org\/10.1016\/j.urolonc.2021.07.019.","journal-title":"Urol Oncol"},{"issue":"6","key":"2040_CR16","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1016\/j.euf.2022.06.002","volume":"8","author":"K Numakura","year":"2022","unstructured":"Numakura K, Kobayashi M, Ishida T, Okane K, Suzuki K, Shimoda N, et al. Effect of levofloxacin on the efficacy and adverse events in intravesical bacillus Calmette-Guerin treatment for bladder cancer: results of a randomized, prospective, multicenter study. Eur Urol Focus. 2022;8(6):1666\u201372.","journal-title":"Eur Urol Focus"},{"issue":"4","key":"2040_CR17","first-page":"671","volume":"69","author":"WS Tan","year":"2016","unstructured":"Tan WS, et al. Systematic review and meta-analysis of the efficacy of hyperthermic intravesical chemotherapy for non\u2013muscle-invasive bladder cancer. Eur Urol. 2016;69(4):671\u201380.","journal-title":"Eur Urol"},{"issue":"1","key":"2040_CR18","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s11255-024-04169-4","volume":"57","author":"EM Akda\u015f","year":"2025","unstructured":"Akda\u015f EM, \u00c7ulha MM, Telli E, Bosnal\u0131 E, Baykal S, Baynal EA, et al. The effect of intravesical chemohyperthermia with mitomycin in non-muscle-invasive bladder tumour patients who cannot tolerate BCG treatment or recur after treatment and refuse cystectomy. Int Urol Nephrol. 2025;57(1):63\u20139.","journal-title":"Int Urol Nephrol"},{"issue":"8","key":"2040_CR19","doi-asserted-by":"publisher","first-page":"3241","DOI":"10.7314\/APJCP.2015.16.8.3241","volume":"16","author":"RG Ekin","year":"2015","unstructured":"Ekin RG, Akarken I, Cakmak O, Tarhan H, Celik O, Ilbey YO, et al. Results of intravesical chemo-hyperthermia in high-risk non-muscle invasive bladder cancer. Asian Pac J Cancer Prev. 2015;16(8):3241\u20135.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"3","key":"2040_CR20","doi-asserted-by":"publisher","first-page":"453","DOI":"10.3390\/cancers17030453","volume":"17","author":"MT Melgarejo-Segura","year":"2025","unstructured":"Melgarejo-Segura MT, Zambudio-Munuera A, Arrabal-Polo M\u00c1, Lardelli-Claret P, Pareja-Vilchez M, Arrabal-Mart\u00edn M. Long-term outcomes of intravesical mitomycin C administered via electromotive drug administration or conductive chemo-hyperthermia in non-muscle-invasive bladder cancer. Cancers. 2025;17(3):453.","journal-title":"Cancers"},{"issue":"6","key":"2040_CR21","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s00345-015-1712-3","volume":"34","author":"TJH Arends","year":"2016","unstructured":"Arends TJH, et al. Safety and efficacy of hyperthermic intravesical chemotherapy using the COMBAT bladder recirculation system. World J Urol. 2016;34(6):859\u201366.","journal-title":"World J Urol"}],"container-title":["BMC Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12894-025-02040-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-025-02040-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-025-02040-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T11:14:47Z","timestamp":1770722087000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12894-025-02040-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,14]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2040"],"URL":"https:\/\/doi.org\/10.1186\/s12894-025-02040-x","relation":{},"ISSN":["1471-2490"],"issn-type":[{"value":"1471-2490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,14]]},"assertion":[{"value":"25 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Gulhane Education and Research Hospital (Approval No: 2024\/236, Date: 28.05.2024). The research was conducted in accordance with the principles of the Declaration of Helsinki. Written informed consent was obtained from all participants prior to treatment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"39"}}